Therapeutic options in gastric cancer: Neoadjuvant chemotherapy vs postoperative chemoradiotherapy

ONCOLOGY

Volumn 21, Issue 9, 2007, Pages 1084-1087

  Jackson, Christopher ^a   Mochlinski, Kazimierz ^a   Cunningham, David ^b  

^a Royal Marsden Hospital

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; MEDICAL RESEARCH; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; PERIOPERATIVE CARE; POSTOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34548337032     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Cancer Research UK: UK stomach cancer statistics. Available at http://info. cancerresearchuk.org/cancerstats/types/stomach/. Accessed July 6, 2007.
2. National Cancer Institute: Stomach (gastric) cancer. Available at http://www.cancer.gov/cancertopics/types/stomach/ Accessed July 6, 2007.
3. Hallissey MT, Dunn JA, Ward LC, et al: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 343:1309-1312, 1994.
4. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35:1059-1064, 1999.
5. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004.
6. Cronin KA, Feuer EJ, Clarke LD, et al: Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: Comparison of mortality results from the cisnet breast cancer base case analysis. J Natl Cancer Inst Monogr (36):112-121, 2006.
7. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007.
8. Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993.
9. Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente), Ann Oncol 11:837-843, 2000.
10. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001.
11. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006.
12. Gunderson LL: Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol 12:150-161, 2002.
13. Macdonald JS, Smalley S, Benedetti J, et al: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008) (abstract 6). Presented at the Gastrointestinal Cancers Symposium, San Francisco, January 22-24, 2004.
14. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Medical Research Council Oesophageal Cancer Working Party. Lancet 359:1727-1733, 2002.
15. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616, 1994.
16. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997.
17. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004, 2002.
18. Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908-914, 1999.
19. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909, 2006.
20. Cunningham D, Rao S, Starling N, et al: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial (abstract LBA4017). J Clin Oncol 24(18S):182s, 2006.